Immune/Inflammatory Disease: Early-Stage R&D Technologies and Dealmaking
Published By: Decision Resources
May 2009
R55-645
PDF E-mail From Publisher $2,250.00
Global Site License Fulfilled by Publisher $4,500.00
Description
Introduction
Today’s leading autoimmune/inflammatory disease drugs are blockbusters, but what are the remaining unmet needs and next opportunities? Dealmaking patterns indicate that Big Pharma continues to look to small technology companies to tap opportunities to treat underserved diseases and offer improved administration options. While the value of the novel agents in development remains unproved, earlystage platforms and pipelines house the next innovations in these disease states.
Get the Answers You Need to Shape Your Strategy
- Although efficacious, current therapies for inflammatory and autoimmune diseases do not successfully
treat all patients. What novel mechanisms of action are in development? What technologies offer treatment potential?
- Much of the innovation in drug discovery and design occurs in small companies. What companies are developing novel approaches to treat inflammatory diseases? What collaborations have they forged with Big Pharma?
- Although the inflammatory cascade is central to most of the autoimmune diseases, the specific etiology
of many diseases remains unknown. What are companies doing to further the understanding of these diseases?
Scope
- Current market: 2008 sales, market-leading products, leading companies.
- Novel targets for drug development: MAP kinases, Janus kinases, toll-like receptors,novel interleukins, NF-ęB, PDE4.
- Novel technologies for drug development: RNA therapeutics, stem-cell therapy.
- Development and dealmaking data: 8 tables that identify developmental compounds and industry and academic alliances.
- Company profiles: Archemix, Array BioPharma, Cellzome, Dynavax, Regulus Therapeutics.
|
Table of Contents
- Executive Summary
- Strategic Considerations
- Stakeholder Implications
- Introduction
- What Market Awaits Innovative Therapies?
- Novel Approaches to Inflammation/Autoimmune Disease Treatment
- Novel Targets
- MAP Kinases
- Jak
- Toll-Like Receptors
- Novel Interleukins
- Nuclear Factor-Kappa B
- Phosphodiesterase 4
- Novel Technologies
- RNA-Based Therapeutics
- Stem-Cell Therapy
- Company Profiles
- Archemix
- Array BioPharma
- Cellzome
- Dynavax
- Regulus Therapeutics
- Outlook
- Tables
- 1. Descriptions of Inflammatory and Autoimmune Diseases
- 2. Top-Selling Autoimmune and Anti-Inflammatory Treatments, 2008
- 3. Common Immune Treatments and their Targets
- 4. MAP Kinase Agents in Clinical Development for Autoimmune and Inflammatory Diseases
- 5. Jak Kinase Agents in Development for Autoimmune and Inflammatory Diseases
- 6. Toll-Like Receptor Agents in Development for Autoimmune and Inflammatory Diseases
- 7. IL-12, IL-17, and IL-23 Agents in Development for Autoimmune and Inflammatory Diseases
- 8. NF-ęB Agents in Development for Autoimmune and Inflammatory Diseases
- 9. PDE4 Agents in Development for Autoimmune and Inflammatory Diseases
- 10. Select Deals in Autoimmune and Inflammatory Disease Drug Development
- 11. Select Academic Collaborations in Autoimmune and Inflammatory Disease Drug Development
- Figures
- 1. Worldwide Sales of Agents to Treat Inflammatory and Autoimmune Diseases, 2003-2008
- 2. Market Share of the Autoimmune and Inflammatory Disease Market by Company, 2008
|
Order Form * Please reference product number R55-645 when ordering or inquiring.
MindBranch, Inc.,
131 Ashland St., Suite 200 North Adams, MA 01247
tel: 800-774-4410
fax: +1-413-664-9791
www.mindbranch.com
|
